Assessing the Role of 21-Gene Assays in Breast Cancer

Video

John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

John H. Ward, MD, Margaret A. Amundsen Endowed Professor of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

Patients who have a low 21-gene recurrence score can be spared chemotherapy. It is predicted that 46% of women with breast cancer can forego chemotherapy, according to Ward.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia

Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia

Jordyn Sava
July 11th 2025
Article

New findings reveal that fixed-duration ibrutinib plus venetoclax offers long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Dr Voorhees on CARTITUDE-1: Cilta-Cel Sets New Bar in Myeloma Survival

Dr Voorhees on CARTITUDE-1: Cilta-Cel Sets New Bar in Myeloma Survival

Jordyn Sava
July 9th 2025
Article

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Real-World Study Shows Differences in Efficacy Among CDK4/6 Inhibitors for Advanced Breast Cancer

Real-World Study Shows Differences in Efficacy Among CDK4/6 Inhibitors for Advanced Breast Cancer

Tony Berberabe, MPH
July 8th 2025
Article

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival for advanced breast cancer patients.

Read More

Luspatercept’s Benefit in MDS: Dr Garcia-Manero on COMMANDS Trial

Luspatercept’s Benefit in MDS: Dr Garcia-Manero on COMMANDS Trial

Jordyn Sava
July 7th 2025
Article

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment standards in hematology.

Read More